Pharmaceutical Launch Sequencing


Setting a global launch sequence for pharmaceutical products requires extensive research, planning and coordination.  Use this report to establish and improve cross-functional coordination, a crucial aspect to managing launch sequences, and work with regulatory teams to manage the licensing cascade.  Set clear roles for final responsibility for approving launch sequences, and understand the latest trends in launches across all market types and launch waves.

Download Now! speak-to-an-expert

Report Details and Features 

From country to county, drug launches happen in a certain order. How do companies develop their pharmaceutical launch sequencing plans? Which markets come first? As much as possible, companies want to prioritize markets where they get the most favorable pricing.

Report details:

  • 3 chapters + an Executive Summary
  • 79 pages
  • 400+ metrics
  • 65+ graphics

Data have been split by team region:

  • United States
  • Europe
  • Emerging Markets

Data have also been split by company size:

  • Top 10
  • Top 50
  • Small

Data highlights include: 

  • Timelines for beginning pharmaceutical launch sequencing planning
    • Current and ideal start times for launch sequencing
  • Organization of launch sequencing responsibilities
  • Metrics for which functions are responsible for approving launch sequencing plans
  • Number of FTEs on dedicated pharmaceutical launch sequencing committees
  • Launch sequencing committee membership
  • Funding dedicated pharmaceutical launch sequencing committees
  • Spending levels for launch sequencing activities
  • Metrics on pharmaceutical launch sequencing development tools
    • Spending levels
    • Approach and use of tools
  • Individual launch sequence budget levels
  • Timeline for developing launch sequence
  • Number of meetings with regulatory groups
  • Frequency of sequence reassessments
  • Prototypical launch sequence
  • Launch wave metrics
    • Division of countries per launch wave
    • Year-over-year trends in first- and second-wave launches

Top Reasons to Read This Pharmaceutical Launch Sequencing Report

Establish and improve cross-functional coordination: Cross-functional coordination is crucial to managing launch sequences. It is especially important when working with regulatory teams to manage the licensing cascade. This study includes detailed best practices and strategies for how companies should work across functions within the organization to coordinate launch sequencing and provide important regulatory and market guidance to shape the product launch. It also includes global launch sequencing budgets and which US or global groups contribute the highest spend.

Involve C-suite executives in final launch sequence approvals: Because launch sequencing has such a large impact on a brand’s potential revenue, C-level executives are best positioned to review and approve plans. This benchmarking study provides detailed data on the composition of committees that determine pharmaceutical launch sequences. It also provides discussion on the advantages and disadvantages of employing dedicated launch sequencing committees.

Shift emerging markets to second wave launches: Large and comparatively wealthy US and European markets are typically high priorities for first launch waves. However, heavily populated emerging markets, such as the BRIC nations, are more commonly following in second wave launches. This report includes data analysis to support moving emerging market launches earlier in the launch sequence. Data include launch sequencing comparisons between 2012 and 2015 earlier in the launch sequence. Data include launch sequencing comparisons between 2012 and 2015.

You may also be interested in our Market Access library

Sample List of Companies that Participated in this Study:

Pharmaceutical launch sequencing participants